Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GnRHa Plus Letrozole in Obese Progestin-insensitive Early-stage Endometrial Cancer
NCT06379113Phase 3Recruiting
- Start
- Jul 2022
- Primary completion
- Mar 2028
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 3 trial of relugolix, letrozole in endometrial cancer (EC), Atypical endometrial hyperplasia (AEH). Started Jul 2022; status: recruiting.
02
Drugs
relugolixletrozole
03
Conditions
endometrial cancer (EC)Atypical endometrial hyperplasia (AEH)
Beyond the preview
Go deeper on NCT06379113.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06379113.